{ 'indexed': {'date-parts': [[2024, 8, 9]], 'date-time': '2024-08-09T00:22:51Z', 'timestamp': 1723162971034},
'reference-count': 0,
'publisher': 'Oxford University Press (OUP)',
'license': [ { 'start': { 'date-parts': [[2024, 8, 8]],
'date-time': '2024-08-08T00:00:00Z',
'timestamp': 1723075200000},
'content-version': 'am',
'delay-in-days': 0,
'URL': 'https://academic.oup.com/pages/standard-publication-reuse-rights'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:title>Abstract</jats:title>\n'
' <jats:p>The COVID-19 pandemic saw the largest deployment of monoclonal '
'antibodies (mAbs) for an infectious disease in history. mAbs to SARS-CoV-2 spike protein '
'proved safe and were initially effective for COVID-19 therapy, but each was defeated by '
'continued SARS-CoV-2 evolution, leading to their withdrawal. This was a setback for people '
'with impaired immunity who cannot mount an effective antibody response to SARS-CoV-2 and '
'often cannot clear the virus. New mAbs have now been developed for pre-exposure prophylaxis '
'(PreEP) in immunosuppressed people. Here we argue that while mAb use for PreEP is justified, '
'single mAbs should not be used for COVID-19 therapy. In contrast to PreEP where the viral '
'inoculum is small, immunosuppressed people with COVID-19 have large viral burden that can '
'harbor mAb-escape variants that single-agent mAb treatments can rapidly select for '
'resistance. Selection of mAb-escape variants has potential risks for patients, society and '
'the feasibility of mAb therapy itself.</jats:p>',
'DOI': '10.1093/cid/ciae408',
'type': 'journal-article',
'created': {'date-parts': [[2024, 8, 8]], 'date-time': '2024-08-08T19:03:44Z', 'timestamp': 1723143824000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral '
'stewardship',
'prefix': '10.1093',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-9402-9167',
'authenticated-orcid': False,
'given': 'Arturo',
'family': 'Casadevall',
'sequence': 'first',
'affiliation': [ { 'name': 'Department of Molecular Microbiology and Immunology, Johns '
'Hopkins School of Public Health , Baltimore, MD'}]},
{ 'given': 'Daniele',
'family': 'Focosi',
'sequence': 'additional',
'affiliation': [ { 'name': 'North-Western Tuscany Blood Bank, Pisa University Hospital , '
'Pisa , Italy'}]},
{ 'given': 'Liise-anne',
'family': 'Pirofski',
'sequence': 'additional',
'affiliation': [ { 'name': 'Divison of Infectious Diseases, Albert Einstein College of '
'Medicine , Bronx, NY'}]},
{ 'given': 'Shmuel',
'family': 'Shoham',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Infectious Diseases, Johns Hopkins School of '
'Medicine , Baltimore, MD'}]}],
'member': '286',
'published-online': {'date-parts': [[2024, 8, 8]]},
'container-title': 'Clinical Infectious Diseases',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae408/58775511/ciae408.pdf',
'content-type': 'application/pdf',
'content-version': 'am',
'intended-application': 'syndication'},
{ 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae408/58775511/ciae408.pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 8, 8]],
'date-time': '2024-08-08T19:03:45Z',
'timestamp': 1723143825000},
'score': 1,
'resource': { 'primary': { 'URL': 'https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae408/7729969'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 8, 8]]},
'references-count': 0,
'URL': 'http://dx.doi.org/10.1093/cid/ciae408',
'relation': {},
'ISSN': ['1058-4838', '1537-6591'],
'subject': [],
'published': {'date-parts': [[2024, 8, 8]]}}
